Close Menu

NEW YORK — Irish diagnostics firm Trinity Biotech said on Tuesday that it has received CE marking for its Captia SARS-CoV-2 IgG ELISA test.

The test uses a recombinant form of SARS-CoV-2 spike protein to detect immunoglobulin G against the virus. Trinity said that the test, which has demonstrated 100 percent specificity, will have applications in detecting past SARS-CoV-2 infection, monitoring individuals who have received SARS-CoV-2 vaccination, and screening individuals prior to vaccination.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.